Completed Phase 2 enrollment with randomization of 51 subjects into treatment and control arms Phase 1/2 study (N=60) demonstrated favorable safety and tolerability profile with no serious adverse ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback